Brain haemorrhage or “brain bleed” is a type of stroke which can cause brain damage and it can be life-threatening also. It mainly results due to bleeding between the brain tissue and skull or within the brain tissue itself.
Some of the common symptoms of Brain haemorrhage include severe headache, seizures, nausea and vomiting, confusion, dizziness, difficulty swallowing, loss of vision or difficulty seeing and many others. Head trauma or injury, high blood pressure, amyloid angiopathy, aneurysm, blood vessel abnormalities are some of the causes for the Brain haemorrhage.
DelveInsight's "Brain Hemorrhage Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Brain Hemorrhage Market, historical and forecasted epidemiology, the pipeline insight as well as the Brain Hemorrhage market size and shares analysis in the seven major markets (7MM) (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Brain Hemorrhage Market Key Facts
As per the stroke association, in the UK, around 15% of strokes are hemorrhagic (due to a bleed), and about 85% are ischaemic (due to a blockage to the blood supply in the brain).
As per the Headway UK, in 2016-17, there were 348,453 UK admissions to hospital with acquired brain injury. That is 531 admissions per 100,000 of the population.
Brain Hemorrhage Market Analysis
The Brain Hemorrhage market analysis section of the report helps to build the detailed comprehension of the historic, current and forecasted Brain Hemorrhage market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Brain Hemorrhage market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Brain Hemorrhage Epidemiology Forecast
The Brain Hemorrhage epidemiology section covers insights about historical and current Brain Hemorrhage patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Brain Hemorrhage Pipeline Analysis and Key Companies
The Brain Hemorrhage Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Brain Hemorrhage market or expected to get launched in the market during the study period. The analysis covers the Brain Hemorrhage market uptake by drugs; patient uptake by therapies; and sales of each drug.
Some of the key companies in the Brain Haemorrhage market include:
Novo Nordisk
Bristol-Myers Squibb
Transition Therapeutics
Abbott
Baxter
OSF Healthcare System
Hoffmann-La Roche
Novartis
Pfizer
And many others.
For more details on Brain Hemorrhage Market Insights, Epidemiology, and Pipeline Analysis, visit: https://www.delveinsight.com/report-store/brain-hemorrhage-market